Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
Patents for C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692)
11/2005
11/03/2005US20050245457 Pseudopeptides growth hormone secretagogues
11/03/2005US20050245453 Peptides derived from cadherin and methods of use thereof
11/03/2005US20050245445 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
11/03/2005US20050245435 Compounds for enzyme inhibition
11/03/2005US20050245432 N-methyl amino acids
11/03/2005US20050244812 Kits and methods for detection of apoptotic cells
11/03/2005US20050244376 Modified viral surface proteins for binding to extracellular matrix components
11/03/2005DE102004018405A1 Antibakterielle Amid-Makrozyklen II Antibacterial amide macrocycles II
11/02/2005EP1590666A1 Compositions and methods for enhancing apoptosis
11/02/2005EP1590442A2 Macrocyclic hepatitis c serine protease inhibitors
11/02/2005EP1590434A2 Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
11/02/2005EP1242363B1 Cd45 inhibitors
11/02/2005EP0973540B1 Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
11/02/2005EP0793675B1 Hiv-1- and hiv-2-peptides for inhibition of membrane fusion-associated events, including hiv transmission
11/02/2005CN1691955A Caspase 9 activation and uses therefor
11/02/2005CN1225472C 5-membered ring compounds
11/02/2005CN1225471C Compounds with growth hormone releasing properties
11/01/2005US6960678 Silanol enzyme inhibitors
11/01/2005US6960648 Peptide transporters that specifically target certain cell types for the delivery of drugs and therapeutic agents
11/01/2005US6960597 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
11/01/2005US6960575 Thiazine derivatives
11/01/2005US6960567 Forming an intermediate compound N-((2S)- thiobenzoyl-4 (1,5,5-trimethylhydantoinyl)butanoyl)-L-leucyl-L- tert-leucine N-methylamide by an improved process that substantially reduces the presence of contaminants in the
11/01/2005US6960565 Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNS) in a tissue, its selection, pharmaceutical compositions and use
11/01/2005US6960559 Neurite growth regulatory factors
10/2005
10/27/2005WO2005100381A2 Processes for preparing eptifibatide and pertinent intermediate compounds
10/27/2005WO2005100380A1 Antibacterial amide macrocycles ii
10/27/2005WO2005100317A1 Process for the preparation of perindopril
10/27/2005WO2005087725A3 Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
10/27/2005WO2005037854A3 Immunogenic peptides
10/27/2005US20050240001 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable
10/27/2005US20050239878 Inhibitors of methionine aminopeptidase-2 and uses thereof
10/27/2005US20050239870 Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents
10/27/2005US20050239829 Novel piperidine compound
10/27/2005US20050239739 Conjugates and compositions for cellular delivery
10/27/2005US20050239716 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
10/27/2005US20050239713 Novel tubulysin analogues
10/27/2005US20050239711 Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
10/27/2005US20050239709 Synthetic antimicrobial polypeptides
10/27/2005US20050239693 Template-fixed peptidomimetics with antibacterial activity
10/27/2005US20050239684 Compounds which inhibit beta-secretase activity and methods of use thereof
10/27/2005US20050239121 Non-aggregating non-quenching oligomers comprising nucleotide analogs; methods of synthesis and use thereof
10/27/2005CA2562843A1 Process for the preparation of perindopril
10/26/2005EP1589029A2 Pyrazinone protease inhibitors
10/26/2005EP1588761A2 Combinatorial strategies for polymer synthesis
10/26/2005EP1587941A1 Method for producing alpha-l-aspartyl-l-phenylalanine-beta-ester and method for producing alpha-l-aspartyl-l-phenylalanine-alpha-methyl ester
10/26/2005EP1587529A2 Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
10/26/2005EP1587405A2 Novel compositions and methods for cancer
10/26/2005EP1246837B1 Oligomers of nonpeptide restricted mimetics of dipeptides or tripeptides and the use thereof in the synthesis of synthetic proteins and polypeptides
10/26/2005CN1688600A Template-fixed peptidomimetics with antibacterial activity
10/26/2005CN1688599A Use of dipeptidyl peptidase IV inhibitor
10/26/2005CN1688598A Linker compound, ligand, and producing method thereof
10/26/2005CN1224707C Intracellular isoform of the interleukin-1 receptor antagonist
10/26/2005CN1224629C Phrazinone protease inhibitors
10/25/2005US6958319 Stability and longer shelf life; bortezomib N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
10/25/2005US6958240 Inhibition of major groove DNA binding proteins by modified polyamides
10/20/2005WO2005098048A1 Protein expression yield enhancement in cell-free protein synthesis systems by addition of antifoam agents
10/20/2005WO2005097828A2 Peptides of cav2.2 that inhibit pain
10/20/2005WO2005097261A1 Method of reducing c-reactive protein using growth hormone secretagogues
10/20/2005WO2005085236A3 Caspase inhibitors and uses thereof
10/20/2005WO2005035525A3 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
10/20/2005WO2005030794B1 Hemiasterlin derivatives and uses thereof
10/20/2005WO2005021494A3 D-amino acid peptides
10/20/2005WO2004103389A3 Means for preventing and treating cellular death and their biological applications
10/20/2005WO2004090103A3 Identification of novel nogo-receptors and methods related thereto
10/20/2005US20050233981 Compounds with growth hormone releasing properties
10/20/2005US20050233979 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid
10/20/2005US20050233978 Novel inhibitors of dipeptidyl peptidase I
10/20/2005US20050233977 form active ester by the reaction of N-terminal protected alanine, triphenylphosphine and hexachloroethane; reacting with glutamine and deprotecting to give dipeptide
10/20/2005US20050233976 Therapeutic methods
10/20/2005US20050233975 Enone cancer therapeutics
10/20/2005US20050233972 Neuropeptides and their use for pest control
10/20/2005US20050233953 Histogranin-like peptides, processes for their preparation and uses thereof
10/20/2005US20050233943 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
10/20/2005US20050233387 Assay method
10/20/2005CA2853272A1 Synthesis of boronic ester and acid compounds
10/20/2005CA2565324A1 Method of reducing c-reactive protein using growth hormone secretagogues
10/20/2005CA2560504A1 Protein expression yield enhancement in cell-free protein synthesis systems by addition of antifoam agents
10/19/2005EP1586641A2 Compounds for the treatment of hypercalcemia and hypocalcemia
10/19/2005EP1586586A2 Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament
10/19/2005EP1586584A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids
10/19/2005EP1586580A2 Process for the purification of daptomycin
10/19/2005EP1585745A1 Fc receptor modulating compounds and compositions
10/19/2005EP1423373B1 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
10/19/2005CN1685064A Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
10/19/2005CN1684693A Boronic acid polyvalent salts for treating thrombosis
10/19/2005CN1683391A Synthetic method for N(2)-L-alanyl-L-glutamine dipeptide
10/19/2005CN1682702A Method for preparing medicine composition capable of inhibiting post infective virus proteinase
10/19/2005CN1223603C Bioactive peptide No.26
10/19/2005CN1223602C Bioactive peptide No.11
10/18/2005US6955888 Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
10/13/2005WO2005095464A1 Hyaluronic acid/methotrexate compound
10/13/2005WO2005095441A1 Epithelial cell growth promoter
10/13/2005WO2005095440A1 BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS
10/13/2005WO2005095403A2 Macrocyclic compounds as inhibitors of viral replication
10/13/2005WO2005094818A1 Azabicyclo-octane inhibitors of iap
10/13/2005WO2005010205A3 Biomarkers fo aggrecanase activity
10/13/2005US20050227926 E.g., 2S [[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide; in particular as inhibitors of HIV protease
10/13/2005US20050227924 Peyer's patch and/or M-cell targeting ligands
10/13/2005US20050227321 Producing antimicrobial peptides (AMPs) by using microbes; not necessary to offset the positive charges of multiple copies of AMPs in multimeric constructs; enables the use of a wider range of multimers and carrier peptides
10/13/2005US20050227291 cyclic peptide consisting of three genetically encodable amino acid residues,at least one of said amino acid residues is a serine, threonine, or cysteine; employed in a variety of research and medical applications, including methods of treating a patient for hepatitis C infection.
1 ... 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 ... 307